Valuation: Biogen Inc.

Market Cap 33.55B 29.61B 28.01B 25.41B 47.63B 3,219B 48.1B 336B 130B 1,644B 126B 123B 5,290B P/E 2026 *
37x
P/E 2027 * 20.1x
Enterprise Value 38.49B 33.96B 32.14B 29.14B 54.64B 3,693B 55.18B 386B 149B 1,886B 145B 141B 6,069B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.38x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.68%
1 week+2.00%
Current month+6.65%
1 month+6.65%
3 months+5.53%
6 months+22.24%
Current year+33.78%
1 week 195.88
Extreme 195.88
201.75
1 month 181.12
Extreme 181.12
201.75
Current year 134.7
Extreme 134.7
201.75
1 year 118.1
Extreme 118.1
201.75
3 years 99
Extreme 99
255.4
5 years 99
Extreme 99
317.45
10 years 99
Extreme 99
351.7
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+2.00% - - 33.55B
+3.13%+11.45%+703.24%+96.98% 81.23B
-0.23%-6.64%+33.84%-8.80% 74.94B
+1.05%+2.78%-7.05%-25.22% 60.9B
-1.07%-0.43%-10.19%+32.27% 47.22B
-1.02%-3.26%-12.89%+162.98% 44.68B
-0.71%+0.76%+63.93%-11.65% 33.55B
-1.30%-2.94%+46.86%+113.26% 24.97B
+0.66%-0.05%+53.21%+95.46% 15.17B
-0.96%-4.71%+26.96%+150.17% 12.9B
Average -0.93%-0.91%+99.77%+67.27% 43.95B
Weighted average by Cap. -1.40%+0.35%+158.37%+51.34%

Financials

2026 *2027 *
Net sales 10.44B 9.22B 8.72B 7.91B 14.83B 1,002B 14.97B 105B 40.32B 512B 39.22B 38.36B 1,647B 10.66B 9.41B 8.9B 8.07B 15.13B 1,023B 15.28B 107B 41.14B 522B 40.02B 39.15B 1,681B
Net income 997M 880M 832M 755M 1.42B 95.65B 1.43B 9.98B 3.85B 48.84B 3.74B 3.66B 157B 1.86B 1.64B 1.55B 1.41B 2.64B 178B 2.66B 18.62B 7.18B 91.08B 6.98B 6.83B 293B
Net Debt 4.94B 4.36B 4.12B 3.74B 7.01B 474B 7.08B 49.45B 19.06B 242B 18.54B 18.13B 778B 2.42B 2.14B 2.02B 1.83B 3.44B 232B 3.47B 24.24B 9.34B 119B 9.09B 8.89B 382B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
30/09/26 €200.60 +0.81% 0
29/09/26 €198.98 -1.37% 3
28/09/26 €201.75 +2.29% 6
25/09/26 €197.24 -0.38% 109
24/09/26 €198.00 +0.68% 186
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
227.07USD
Average target price
238.18USD
Spread / Average Target
+4.89%

Quarterly revenue - Rate of surprise